Bactericidal activity and biocompatibility of ceragenin-coated magnetic nanoparticles

Journal of Nanobiotechnology

Volumn 13, Issue 1, 2015, Pages

  Niemirowicz, Katarzyna ^a   Surel, Urszula ^a   Wilczewska, Agnieszka Z ^b   Mystkowska, Joanna ^c   Piktel, Ewelina ^a   Gu, Xiaobo ^d   Namiot, Zbigniew ^a   Kulakowska, Alina ^a   Savage, Paul B ^d   Bucki, Robert ^a,e  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF BIALYSTOK   (Poland)

^c BIALYSTOK UNIVERSITY OF TECHNOLOGY   (Poland)

^d Brigham Young University   (United States)

^e JAN KOCHANOWSKI UNIVERSITY   (Poland)

Author keywords

Antibacterial activity; Ceragenins; Magnetic nanoparticles; Pseudomonas aeruginosa

Indexed keywords

ANTIMICROBIAL AGENTS; ATOMIC FORCE MICROSCOPY; BACTERIA; BACTERICIDES; BIOCOMPATIBILITY; BIOFILMS; CRYSTAL ATOMIC STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; FOURIER TRANSFORM INFRARED SPECTROSCOPY; MAGNETISM; NANOPARTICLES; NANOSYSTEMS; SCANNING ELECTRON MICROSCOPY; SYNTHESIS (CHEMICAL); THERMOGRAVIMETRIC ANALYSIS; TRANSMISSION ELECTRON MICROSCOPY;

ANTI-BACTERIAL ACTIVITY; ANTIBACTERIAL PEPTIDES; BACTERICIDAL ACTIVITY; CERAGENINS; FOURIER TRANSFORM INFRA RED (FTIR) SPECTROSCOPY; MAGNETIC NANO-PARTICLES; PHYSICOCHEMICAL PROPERTY; PSEUDOMONAS AERUGINOSA;

NANOMAGNETICS;

ANTIINFECTIVE AGENT; CERAGENIN; CRYSTAL VIOLET; HEMOGLOBIN; MAGNETIC NANOPARTICLE; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; CERAGENIN CSA-13; MAGNETITE NANOPARTICLE; STEROID;

ANTIBACTERIAL ACTIVITY; ARTICLE; ATOMIC FORCE MICROSCOPY; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BIOCOMPATIBILITY; BIOFILM; BODY FLUID; CELL STRUCTURE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; ERYTHROCYTE; HEMOLYSIS; HOST CELL; INFRARED SPECTROSCOPY; MEMBRANE PERMEABILITY; PHYSICAL CHEMISTRY; PSEUDOMONAS AERUGINOSA; THERMOGRAVIMETRY; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; CHEMISTRY; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; BIOFILMS; CALORIMETRY, DIFFERENTIAL SCANNING; ERYTHROCYTES; HUMANS; MAGNETITE NANOPARTICLES; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, TRANSMISSION; PSEUDOMONAS AERUGINOSA; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STEROIDS; THERMOGRAVIMETRY;

EID: 84931041595     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/s12951-015-0093-5     Document Type: Article

References (58)

1. Chin JN, Jones RN, Sader HS, Savage PB, Rybak MJ. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. J Antimicrob Chemother. 2008;61(2):365-70.
2. Hoppens MA, Wheeler ZE, Qureshi AT, Hogan K, Wright A, Stanley GG, et al. Maghemite, silver, ceragenin conjugate particles for selective binding and contrast of bacteria. J Colloid Interface Sci. 2014;413:167-74.
3. Isogai E, Isogai H, Takahashi K, Okumura K, Savage PB. Ceragenin CSA-13 exhibits antimicrobial activity against cariogenic and periodontopathic bacteria. Oral Microbiol Immunol. 2009;24(2):170-2.
4. Kuroda K, Fukuda T, Okumura K, Yoneyama H, Isogai H, Savage PB, et al. Ceragenin CSA-13 induces cell cycle arrest and antiproliferative effects in wild-type and p53 null mutant HCT116 colon cancer cells. Anticancer Drugs. 2013;24(8):826-34.
5. Polat ZA, Savage PB, Genberg C. In vitro amoebicidal activity of a ceragenin, cationic steroid antibiotic-13, against Acanthamoeba castellanii and its cytotoxic potential. J Ocul Pharmacol Ther. 2011;27(1):1-5.
6. Howell MD, Streib JE, Kim BE, Lesley LJ, Dunlap AP, Geng D, et al. Ceragenins: a class of antiviral compounds to treat orthopox infections. J Invest Dermatol. 2009;129(11):2668-75.
7. Lai XZ, Feng Y, Pollard J, Chin JN, Rybak MJ, Bucki R, et al. Ceragenins: cholic acidbased mimics of antimicrobial peptides. Acc Chem Res. 2008;41(10):1233-40.
8. Van Bambeke F, Mingeot-Leclercq MP, Struelens MJ, Tulkens PM. The bacterial envelope as a target for novel anti-MRSA antibiotics. Trends Pharmacol Sci. 2008;29(3):124-34.
9. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacol Rep. 2012;64(5):1020-37.
10. Giannaccini M, Giannini M, Calatayud MP, Goya GF, Cuschieri A, Dente L. Magnetic nanoparticles as intraocular drug delivery system to target retinal pigmented epithelium (RPE). Int J Mol Sci. 2013;15(1):1590-605.
11. Tate JA, Petryk AA, Giustini AJ, Hoopes PJ. In vivo biodistribution of iron oxide nanoparticles: an overview. Proc SPIE. 2011;7901:790117.
12. Singh RK, Patel KD, Kim JJ, Kim TH, Kim JH, Shin US et al. Multifunctional Hybrid Nanocarrier: Magnetic CNTs Ensheathed with Mesoporous Silica for Drug Delivery and Imaging System. ACS Appl Mater Interfaces; 2014; 6(4):2201-8
13. He X, Liu F, Liu L, Duan T, Zhang H, Wang Z. Lectin-conjugated Fe2O3@Au core@shell nanoparticles as dual mode contrast agents for in vivo detection of tumor. Mol Pharm. 2014; 11(3):738-45
14. Niemirowicz K, Markiewicz KH, Wilczewska AZ, Car H. Magnetic nanoparticles as new diagnostic tools in medicine. Adv Med Sci. 2012;57(2):196-207.
15. Dionigi C, Lungaro L, Goranov V, Riminucci A, Piñeiro-Redondo Y, Bañobre-López M et al. Smart magnetic poly(N-isopropylacrylamide) to control the release of bio-active molecules. J Mater Sci Mater Med. 2014; 25(10):2365-71.
16. Massart R. Preparation of aqueous magnetic liquids in alkaline and acidic media. IEEE Trans Magn. 1981;17(2):1247-8.
17. Calkosinski I, Dobrzynski M, Calkosinska M, Seweryn E, Bronowicka-Szydelko A, Dzierzba K, et al. [Characterization of an inflammatory response]. Postepy Hig Med Dosw (Online). 2009;63:395-408.
18. Kellum JA. Metabolic acidosis in patients with sepsis: epiphenomenon or part of the pathophysiology? Crit Care Resusc. 2004;6(3):197-203.
19. Brotman RM. Vaginal microbiome and sexually transmitted infections: an epidemiologic perspective. J Clin Invest. 2011;121(12):4610-7.
20. Bowler PG, Duerden BI, Armstrong DG. Wound microbiology and associated approaches to wound management. Clin Microbiol Rev. 2001;14(2):244-69.
21. Fu Y, Kao WJ. Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems. Expert Opin Drug Deliv. 2010;7(4):429-44.
22. Leszczynska K, Namiot A, Fein DE, Wen Q, Namiot Z, Savage PB, et al. Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice. BMC Microbiol. 2009;9:187.
23. Huang X, Brazel CS. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release. 2001;73(2-3):121-36.
24. Hussein-Al-Ali SH, El Zowalaty ME, Hussein MZ, Ismail M, Webster TJ. Synthesis, characterization, controlled release, and antibacterial studies of a novel streptomycin chitosan magnetic nanoantibiotic. Int J Nanomedicine. 2014;9:549-57.
25. Niemirowicz K, Swiecicka I, Wilczewska AZ, Misztalewska I, Kalska-Szostko B, Bienias K, et al. Gold-functionalized magnetic nanoparticles restrict growth of Pseudomonas aeruginosa. Int J Nanomedicine. 2014;9:2217-24.
26. Movahedi Z, Pourakbari B, Mahmoudi S, Sabouni F, Ashtiani Haghi MT, Hosseinpour Sadeghi R, et al. Pseudomonas aeruginosa infection among cystic fibrosis and ICU patients in the referral children medical hospital in Tehran, Iran. J Prev Med Hyg. 2013;54(1):24-8.
27. Trandafir LM, Moscalu M, Diaconu G, Cîrdeiu E, Tudose AA, Coman G, et al. The impact of respiratory tract infections on the nutritional state of children with cystic fibrosis. Rev Med Chir Soc Med Nat Iasi. 2013;117(4):863-9.
28. Leszczynska K, Namiot A, Cruz K, Byfield FJ, Won E, Mendez G, et al. Potential of ceragenin CSA-13 and its mixture with pluronic F-127 as treatment of topical bacterial infections. J Appl Microbiol. 2011;110(1):229-38.
29. Carmona-Ribeiro AM, de Melo Carrasco LD. Novel formulations for antimicrobial peptides. Int J Mol Sci. 2014;15(10):18040-83.
30. Thach CV, Hai NH, Chau N. Size controlled magnetite nanoparticles and their drug loading ability. J Korean Phys Soc. 2008;52(5):1332-5.
31. Hussein-Al-Ali SH, El Zowalaty ME, Kura AU, Geilich B, Fakurazi S, Webster TJ, et al. Antimicrobial and controlled release studies of a novel nystatin conjugated iron oxide nanocomposite. Biomed Res Int. 2014;2014:651831.
32. Costa F, Carvalho IF, Montelaro RC, Gomes P, MartinsMC. Covalent immobilization of antimicrobial peptides (AMPs) onto biomaterial surfaces. Acta Biomater. 2011;7(4):1431-40.
33. Zhao L, Chu PK, Zhang Y, Wu Z. Antibacterial coatings on titanium implants. J Biomed Mater Res B Appl Biomater. 2009;91(1):470-80.
34. Kierys A. Synthesis of Aspirin-loaded Polymer-Silica Composites and their Release Characteristics. ACS Appl Mater Interfaces; 2014;6(16):14369-76.
35. Cantón R, Fernández Olmos A, de la Pedrosa EG, del Campo R, Antonia Meseguer M. [Chronic bronchial infection: the problem of Pseudomonas aeruginosa]. Arch Bronconeumol. 2011;47 Suppl 6:8-13.
36. Cervia JS, Ortolano GA, Canonica FP, McAlister MB. Role of biofilm in Pseudomonas aeruginosa colonization and infection. Infect Control Hosp Epidemiol. 2009;30(9):925-7.
37. de Bentzmann S, Plésiat P. The Pseudomonas aeruginosa opportunistic pathogen and human infections. Environ Microbiol. 2011;13(7):1655-65.
38. Nagant C, Pitts B, Stewart PS, Feng Y, Savage PB, Dehaye JP. Study of the effect of antimicrobial peptide mimic, CSA-13, on an established biofilm formed by Pseudomonas aeruginosa. Microbiologyopen. 2013;2(2):318-25.
39. Nagant C, Feng Y, Lucas B, Braeckmans K, Savage P, Dehaye JP. Effect of a low concentration of a cationic steroid antibiotic (CSA-13) on the formation of a biofilm by Pseudomonas aeruginosa. J Appl Microbiol. 2011;111(3):763-72.
40. Leuba KD, Durmus NG, Taylor EN, Webster TJ. Short communication: carboxylate functionalized superparamagnetic iron oxide nanoparticles (SPION) for the reduction of S. aureus growth post biofilm formation. Int J Nanomedicine. 2013;8:731-6.
41. Sathyanarayanan MB, Balachandranath R, Genji Srinivasulu Y, Kannaiyan SK, Subbiahdoss G. The effect of gold and iron-oxide nanoparticles on biofilm-forming pathogens. ISRN Microbiol. 2013;2013:272086.
42. Hetrick EM, Shin JH, Paul HS, Schoenfisch MH. Anti-biofilm efficacy of nitric oxide-releasing silica nanoparticles. Biomaterials. 2009;30(14):2782-9.
43. Abdelghany SM, Quinn DJ, Ingram RJ, Gilmore BF, Donnelly RF, Taggart CC, et al. Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection. Int J Nanomedicine. 2012;7:4053-63.
44. Hiemstra PS. Antimicrobial peptides in the real world: implications for cystic fibrosis. Eur Respir J. 2007;29(4):617-8.
45. Sieprawska-Lupa M, Mydel P, Krawczyk K, Wójcik K, Puklo M, Lupa B, et al. Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob Agents Chemother. 2004;48(12):4673-9.
46. Glukhov E, Burrows LL, Deber CM. Membrane interactions of designed cationic antimicrobial peptides: the two thresholds. Biopolymers. 2008;89(5):360-71.
47. Bucki R, Sostarecz AG, Byfield FJ, Savage PB, Janmey PA. Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum. J Antimicrob Chemother. 2007;60(3):535-45.
48. Drašler B, Drobne D, Novak S, Valant J, Boljte S, Otrin L, et al. Effects of magnetic cobalt ferrite nanoparticles on biological and artificial lipid membranes. Int J Nanomedicine. 2014;9:1559-81.
49. Machen TJ, Hoppens MA, Qureshi AT, Hayes DJ. The hemocompatibility of the synthetic antimicrobial compound CSA-124 and CSA-124 bound to silver nanoparticles. 2014.
50. Ruden S, Hilpert K, Berditsch M, Wadhwani P, Ulrich AS. Synergistic interaction between silver nanoparticles and membrane-permeabilizing antimicrobial peptides. Antimicrob Agents Chemother. 2009;53(8):3538-40.
51. Li Y, Liu J, Zhong Y, Zhang J, Wang Z, Wang L, et al. Biocompatibility of Fe3O4@Au composite magnetic nanoparticles in vitro and in vivo. Int J Nanomedicine. 2011;6:2805-19.
52. Wu W, Chen B, Cheng J, Wang J, Xu W, Liu L, et al. Biocompatibility of Fe3O4/DNR magnetic nanoparticles in the treatment of hematologic malignancies. Int J Nanomedicine. 2010;5:1079-84.
53. Thill A, Zeyons O, Spalla O, Chauvat F, Rose J, Auffan M, et al. Cytotoxicity of CeO2 nanoparticles for Escherichia coli. Physico-chemical insight of the cytotoxicity mechanism Environ Sci Technol. 2006;40(19):6151-6.
54. De D, Mandal SM, Gauri SS, Bhattacharya R, Ram S, Roy SK. Antibacterial effect of lanthanum calcium manganate (La0.67Ca0.33MnO3) nanoparticles against Pseudomonas aeruginosa ATCC 27853. J Biomed Nanotechnol. 2010;6(2):138-44.
55. Brayner R, Ferrari-Iliou R, Brivois N, Djediat S, Benedetti MF, Fiévet F. Toxicological impact studies based on Escherichia coli bacteria in ultrafine ZnO nanoparticles colloidal medium. Nano Lett. 2006;6(4):866-70.
56. Wilczewska A, Markiewicz K. Surface-initiated RAFT/MADIX polymerization on xanthate-coated iron oxide nanoparticles. Macromol Chem Phys. 2014;215(2):190-7.
57. du Noüy PL. An interfacial tensiometer for universal use. J Gen Physiol. 1925;7(5):625-31.
58. Bucki R, Leszczynska K, Byfield FJ, Fein DE, Won E, Cruz K, et al. Combined antibacterial and anti-inflammatory activity of a cationic disubstituted dexamethasone-spermine conjugate. Antimicrob Agents Chemother. 2010;54(6):2525-33.